19 Preclinical CD3-based mouse models for evaluation of bi-specific T-cell engager antibodies by Chang Liu, Chong Li, Chengzhang Shang, Jay Zhang, Yuelei Shen

1163 A novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, BCG033, demonstrates preclinical efficacy against triple-negative breast cancer xenografts by Yi Yang, W Frank An, Chaoshe Guo, Chengzhang Shang, Gao An, Sufei Yao

1165 Preclinical evaluation of fully human bispecific antibody-drug candidates targeting HER3 and the juxtamembrane region of MUC1 by Yi Yang, Nannan Wang, W Frank An, Chaoshe Guo, Chengzhang Shang, Yifu Zhang, Gao An

1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types by Yi Yang, W Frank An, Chaoshe Guo, Chengzhang Shang, Gao An, Zhuolin Li, Zhenyan Han

1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models by Yi Yang, Yuming Guo, W Frank An, Chaoshe Guo, Chengzhang Shang, Gao An, Zhuolin Li, Xuewa Guan

1164 BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy in vivo by Hao Li, Yi Yang, Xiaopeng Li, Jia Zhang, Anqi Wang, W Frank An, Chaoshe Guo, Chengzhang Shang, Yifu Zhang, Yuji Liu, Gao An

1150 DM005, an EGFR × MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models by Jun Li, Hao Li, Yi Yang, Yujie Liu, Baihong Liu, W Frank An, Chaoshe Guo, Chengzhang Shang, Yuelei Shen, Gao An, Yanfei Han, Zhuolin Li, Zhenyan Han, Wenjuan Dai, Zixu Cui, Wanjun Hao